TLDR:
- LifeMD’s Q3 2025: 18% telehealth revenue growth and 30% adjusted EBITDA rise.
- LifeMD boosts telehealth subscriber base by 14%, reaching 310K.
- LifeMD divests WorkSimpli, strengthens financial position with $23.8M in cash.
- LifeMD projects 24% revenue growth for full-year 2025, with strong EBITDA increase.
- LifeMD’s expansion into behavioral health and women’s health drives success.
LifeMD, Inc. (LFMD) saw a 2.16% increase in its stock price, closing at $4.73 on the latest market close.
LifeMD, Inc., LFMD
The company has shown solid progress in its financial results for the third quarter of 2025. LifeMD reported significant growth in its telehealth business, including an 18% rise in revenue and a 30% increase in adjusted EBITDA, reflecting its ongoing success in the sector. The company’s strong performance in telehealth and its strategic moves, such as the divestiture of its majority interest in WorkSimpli, have positioned it well for future growth.
Strong Telehealth Performance Drives Revenue and Subscriber Growth
LifeMD achieved a notable 18% increase in telehealth revenue, which reached $47.3 million for the quarter. The company’s telehealth subscriber base also grew, rising by 14% year-over-year to reach approximately 310,000 active subscribers. This solid growth comes amid competitive challenges, particularly in the weight management market, where low-price providers have increased pressure. Despite these challenges, LifeMD’s strategic initiatives in diversifying its platform, including expanding into behavioral health, women’s health, and hormone therapy, have paid off.
LifeMD’s RexMD business also returned to growth, adding nearly 10,000 new subscribers during the quarter. Additionally, the company’s gross margin for telehealth services, excluding WorkSimpli, stood at 86%, slightly down from 89% in the previous year. The company continues to focus on strengthening its service offerings and expanding its platform to attract and retain more customers across various health sectors.
LifeMD Reports Strong Adjusted EBITDA Growth and Financial Position
LifeMD’s adjusted EBITDA for the quarter increased by 30% year-over-year, totaling $5.1 million. Telehealth’s adjusted EBITDA grew to $2.9 million, up from $2.2 million in Q3 2024. The company’s ability to improve its profitability reflects ongoing operational efficiencies and strategic decisions aimed at enhancing long-term growth. The sale of its majority stake in WorkSimpli further bolstered its balance sheet, helping the company pay off outstanding debts and strengthen liquidity.
For the full year, LifeMD expects a 24% increase in revenue, estimating a range of $192 million to $193 million. Its adjusted EBITDA for 2025 is projected to grow by 254%, reaching between $13.5 million and $14.5 million. The company’s solid financial foundation, with cash totaling $23.8 million as of September 30, 2025, positions it for continued success in the upcoming quarters.
LifeMD’s strong Q3 results highlight the company’s continued expansion in telehealth services and its ability to adapt to a rapidly evolving healthcare market. The company’s focus on expanding its virtual care and pharmacy platform, alongside its commitment to enhancing patient care, sets it up for sustained growth heading into 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
